Literature DB >> 15816877

CTLA4 engagement is required for induction of murine liver transplant spontaneous tolerance.

Wei Li1, Xin Xiao Zheng, Christian S Kuhr, James D Perkins.   

Abstract

Liver transplantation in mice is accepted spontaneously in all strain combinations. The mechanisms remain largely undefined. We hypothesize that signaling via the B7-CTLA4 receptor pathway is required for induction of liver transplant tolerance. Liver transplantation was performed from B10 (H2(b)) to C3H (H2(k)) mice. The recipients received anti-mouse CTLA4 mAb 0.25 mg i.p. every other day post-operatively. Liver grafts in anti-CTLA4 mAb treated recipients were acutely rejected. The allo-specific proliferative responses, anti-donor CTL and NK cell activities of GIC and SC and the serum levels of IFN-gamma and IL-2 from anti-CTLA4 mAb treated recipients were elevated significantly in comparison to the control mice. The frequency of IFN-gamma and IL-2 producing cells were markedly increased also in the anti-CTLA4 treated recipients. The immunohistology of liver grafts from anti-CTLA4 mAb treated mice showed extensively increased lymphocyte infiltration in the portal and general parenchymal areas, and expanded T-cell area in the spleen, with a reduction in the frequency of apoptotic cells observed by TUNEL staining compared with control mice. Thus CTLA4 signaling is critical for murine liver transplant tolerance induction. CTLA4 blockade promotes donor specific T-cell activation, cytotoxicity and Th1 polarization; protects alloreactive T cells from apoptotic death and induces liver allograft acute rejection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15816877     DOI: 10.1111/j.1600-6143.2005.00823.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  24 in total

Review 1.  Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets.

Authors:  Peter J Bugelski; Pauline L Martin
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 2.  Lessons and limits of mouse models.

Authors:  Anita S Chong; Maria-Luisa Alegre; Michelle L Miller; Robert L Fairchild
Journal:  Cold Spring Harb Perspect Med       Date:  2013-12-01       Impact factor: 6.915

3.  Immune Checkpoint Inhibitors and the Risk of Allograft Rejection: A Comprehensive Analysis on an Emerging Issue.

Authors:  Luis E Aguirre; Maria E Guzman; Gilberto Lopes; Judith Hurley
Journal:  Oncologist       Date:  2018-11-09

Review 4.  Liver graft rejection following immune checkpoint inhibitors treatment: a review.

Authors:  Bo Hu; Xiao-Bo Yang; Xin-Ting Sang
Journal:  Med Oncol       Date:  2019-10-11       Impact factor: 3.064

Review 5.  Environmental peer pressure: CD4+ T cell help in tolerance and transplantation.

Authors:  Dana Tedesco; Arash Grakoui
Journal:  Liver Transpl       Date:  2018-01       Impact factor: 5.799

6.  Co-expression of sCD40LIg and CTLA4Ig mediated by adenovirus prolonged mouse skin allograft survival.

Authors:  Zhao-lun Li; Pu-xun Tian; Wu-jun Xue; Jun Wu
Journal:  J Zhejiang Univ Sci B       Date:  2006-06       Impact factor: 3.066

7.  DAP12 deficiency in liver allografts results in enhanced donor DC migration, augmented effector T cell responses and abrogation of transplant tolerance.

Authors:  O Yoshida; S Kimura; L Dou; B M Matta; S Yokota; M A Ross; D A Geller; A W Thomson
Journal:  Am J Transplant       Date:  2014-06-16       Impact factor: 8.086

Review 8.  T Cell Cosignaling Molecules in Transplantation.

Authors:  Mandy L Ford
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

Review 9.  B-cell and T-cell epitopes in anti-factor VIII immune responses.

Authors:  Kathleen P Pratt; Arthur R Thompson
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

10.  CpG oligodeoxynucleotide triggers the liver inflammatory reaction and abrogates spontaneous tolerance.

Authors:  Lian-Li Ma; Xiudan Gao; Liping Liu; Zhidan Xiang; Timothy S Blackwell; Philip Williams; Ravi S Chari; Deng-Ping Yin
Journal:  Liver Transpl       Date:  2009-08       Impact factor: 5.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.